Quanterix : to Acquire Akoya Biosciences Presentation
QTRX
First Integrated Solution for Ultra- Sensitive Detection of Blood and Tissue Based Protein Biomarkers
Uniquely positioned to speed up market development of new diagnostic testing solutions
January 10, 2025
Legal Information
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS (CONTD.)
All forward-looking statements, expressed or implied, included in this presentation are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix's or Akoya's underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix and Akoya anticipate. Quanterix and Akoya caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Neither Quanterix nor Akoya assumes any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.
USE OF FINANCIAL PROJECTIONS
This presentation contains projected financial information with respect to the combined company that will result from the proposed transaction, if consummated. Such projected financial information constitutes forward-looking information, is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such projected financial information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the projected financial information. Actual results may differ materially from the results contemplated by the projected financial information contained in this presentation, and the inclusion of such information in this presentation should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved. Neither Quanterix's nor Akoya's independent auditors have audited, reviewed, compiled or performed any procedures with respect to the projections for purposes of their inclusion in this presentation, and accordingly, neither of them expressed an opinion or provided any other form of assurance with respect thereto for purposes of this presentation.
USE OF NON-GAAP FINANCIAL MEASURES
To supplement Quanterix's preliminary financial information presented on a GAAP basis, Quanterix has provided certain non-GAAP financial measures, including non-GAAP gross margin. Management uses these non-GAAP measures to evaluate our operating performance in manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. Management believes that presentation of these non-GAAP measures provides useful information to investors in assessing our operating performance within our industry and in order to allow comparability to the presentation of other companies in our industry. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with GAAP.
Unless otherwise specified, all information contained herein is provided as of September 30, 2024.
3
Transaction Overview
Consideration
All-stock transaction
AKYA shareholders to receive 0.318x QTRX shares per share of AKYA
Ownership
QTRX shareholders to own ~70% of combined entity
AKYA shareholders to own ~30% of combined entity
AKYA will nominate 2 candidates to join QTRX's Board of Directors, with the total Board size
Governance
at 9 members
Masoud Toloue will serve as Chief Executive Officer and Vandana Sriram will serve as Chief
Financial Officer; combined company will continue to operate under the Quanterix name
Expected transaction close in Q2 2025
Timing
Subject to shareholder approvals and regulatory approvals and other customary closing conditions
Shareholders owning more than 50% of AKYA common stock have entered into
a voting agreement in support of the transaction
4
Accelerated Path to Scale and Profitability with Focus on High Growth Markets
01 Growth
Scale
Efficiency
Acceleration
Strong Runway
Attractive growth expected in a $5B1 addressable market
Combined revenue of ~$220M2
Expected strong double-digit organic revenue growth by 2026
Significant annual cost synergies of ~$40M by end of 2026 (~$20M by end of year 1 post close)
Path to cash flow positive in 2026
Significant combined balance sheet with ~$ 175M3 in cash expected at time of closing
5
Continued Execution of Quanterix's Growth Plan
Grow Menu
Expand
into adjacencies
Translate
into AD Diagnostics
8
Disclaimer
Quanterix Corporation published this content on January 10, 2025, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 10, 2025 at 15:59:07.692.